Monika F Parisi

Learn More
INTRODUCTION Despite a clinically relevant, statistically significant survival benefit with nab-paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer(More)
AIM With the aggregation of real-world data in healthcare, opportunities for outcomes research are growing. In this study, we summarize published literature examining comparative effectiveness(More)
BACKGROUND We compared real-world treatment patterns, resource utilization, and cost of care for patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel + gemcitabine or(More)
BACKGROUND The economic burden of metastatic pancreatic cancer (mPC) is substantial while treatment options are limited. Little is known about the treatment patterns and healthcare costs among mPC(More)
293 Background: In a phase III study in MBC, nab-P demonstrated anti-tumor activity across lines of therapy. Eribulin is indicated for the treatment (Tx) of MBC in pts who have previously received ≥(More)
withHRof 0.55, 0.56, 0.43, 0.16 for age groups<45, 75-79, 80-84, and >85, respectively(P < 1x10). LC survivors with carcinoma, NOS or carcinoid had significantly reduced risks versus(More)
  • 1